Clinical trials: Chronic HCV Infection, active
HCV, HEPATITIS C VIRUS CHRONIC INFECTION
Scaling Up Point-of-Care Hepatitis C Testing and Treatment in Canada
The SCALE-POCT study is a national initiative designed to provide robust evidence for scaling up point-of-care hepatitis C testing for key populations.
- Trial name
- SCALE POCT (NCT07095192)
- Testing
- Preimplementation of HCV Point of care testing
- Where
- 12 sites in Canada
- Volunteers
- 300 people
- Sponsor
- McGill University
Chronic Hepatitis C, Intravenous Drug Usage
Enhancing Access to Care for Chronic Hepatitis C Infected Populations in Hong Kong
In the current era of highly effective direct acting antiviral (DAA) therapy, the remaining obstacles to elimination of chronic HCV infection are identification of the high-risk groups, linkage to continued care and prevention of…
- Trial name
- NCT03993925
- Where
- Hong Kong
- Volunteers
- 800 people
- Sponsor
- The University of Hong Kong
Hepatitis B， Chronic, Hepatitis C
The HOPE Study: Characterizing Patients With Hepatitis B and C
This is an observational, longitudinal, prospective study for sample collection and evaluation for future therapy or disease progression of chronic hepatitis B and C.
- Trial name
- NCT02995252
- Testing
- Blood draws, Tenofovir Alafenamide, Knowledge Index Questionnaire
- Where
- 2 sites in United States
- Volunteers
- 550 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Hepatitis C, Chronic
Nation-wide Hepatitis C Virus (HCV) Registry in Taiwan
To determine the treatment efficacy, safety and long-term outcomes of chronic hepatitis C patients receiving directly acting antivirals in Taiwan
- Trial name
- NCT03200379
- Testing
- directly acting antivirals (DAAs)
- Where
- Taiwan
- Volunteers
- 150,000 people
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Autoimmune Diseases, Lupus Erythematosus, Systemic
Comparative Autoantibody and Immunologic Cell Marker Study
The purpose of this study is to compare immune phenotype, function, and specificity of B lymphocytes from different developmental stages in autoimmune patients to B cells from infectious disease patients and healthy controls.
- Conditions
- Autoimmune Diseases, Lupus Erythematosus, Systemic, Communicable Diseases
- Trial name
- NCT02422875
- Where
- 3 sites in United States
- Volunteers
- 2,500 people, healthy volunteers welcome
- Sponsor
- Emory University
Viral Hepatitis C
SVR12 in Genotype 3 HCV (F0-F2) Treated With RDV + SOF
This study will follow a group of people with chronic hepatitis C infection of genotype 3 who have mild to moderate liver fibrosis (stages F0-F2, measured by a liver stiffness test).
- Trial name
- NCT07316842
- Where
- Russia
- Volunteers
- 30 people
- Sponsor
- Center of target therapy
Hepatitis C, Chronic, Pregnancy; Infection
Sofosbuvir/Velpatasvir Treatment of Chronic Hepatitis C During Pregnancy
This is a multicenter, single arm study of Sofosbuvir/Velpatasvir (SOF/VEL) for treatment of chronic hepatitis C infection during pregnancy.
- Trial name
- STORC (NCT05140941)
- Testing
- Sofosbuvir/Velpatasvir 400 MG-100 MG Oral Tablet
- Where
- 9 sites in United States, Canada
- Volunteers
- 100 people
- Sponsor
- Catherine Anne Chappell
Liver Cirrhosis, Hepatitis B, Chronic
Use of Gender, Age, Alfa-fetoprotein (AFP), and Des-gamma-carboxyprothrombin (PIVKA-II) or GAAD Score in Addition to Ultrasound for Surveillance of People At-risk for Developing Hepatocellular Carcinoma in Asia in Order to Detect Early Liver Cancer
HCC surveillance is currently limited by underutilization and the suboptimal performance of AFP. This prospective, single-arm study investigates whether the GAAD score (Gender, Age, AFP, and PIVKA-II) enhances HCC detection when…
- Conditions
- Liver Cirrhosis, Hepatitis B, Chronic, Hepatitis C, Chronic, Carcinoma, Hepatocellular
- Trial name
- STOPHCC-GAAD (NCT07298577)
- Testing
- PIVKA-II and GAAD score calculation
- Where
- Thailand
- Volunteers
- 2,100 people
- Sponsor
- Siriraj Hospital
NSCLC Stage IV, HIV
Nivolumab/Ipilimumab and Chemotherapy Combination in Advanced NSCLC Patients With HIV, HBV, HCV and Long Covid Syndrome
Study type: Phase 2 - Interventional Trial Number of patients to be enrolled: 105 Participating countries: Italy Study drugs: nivolumab and ipilimumab Cohort A: HBV and HCV patients Cohort B: HIV patients Cohort C: Long COVID…
- Conditions
- NSCLC Stage IV, HIV, HBV, HCV
- Trial name
- LUNGVIR (NCT05597800)
- Testing
- Nivolumab and Ipilimumab
- Where
- Italy
- Volunteers
- 105 people
- Sponsor
- Universita di Verona
Liver Disease Chronic, HEPATITIS C VIRUS CHRONIC INFECTION
Evaluation of the Hepatoprotective Effects of a Nutritional Supplement in Patients With Liver Disease Secondary to Chronic Hepatitis C Virus Infection (RESQUETI Study).
The purpose of this clinical trial is to evaluate whether a nutritional supplement containing resveratrol, quercetin, taurine, inulin, and whey protein improves biochemical and molecular markers, as well as clinical outcomes, in…
- Trial name
- RESQUETI (NCT07487623)
- Testing
- resveratrol, quercetin, taurine, whey protein, and inulin, whey protein
- Where
- 2 sites in Mexico
- Volunteers
- 26 people
- Sponsor
- University of Guadalajara
Carcinoma, Hepatocellular, Hepatitis C, Chronic
Digitalized Surveillance Management for Liver Cancer Risk Population in Improving Eearly Diagnosis Efficancy in Chinese Population (dSEARCH)
The goal of this study is to evaluate whether the standardized liver cancer risk stratification management can effectively improve the early diagnosis rate of liver cancer in the targeted risk population in China.
- Conditions
- Carcinoma, Hepatocellular, Hepatitis C, Chronic, Hepatitis B, Chronic, Cirrhosis, Liver
- Trial name
- dSEARCH (NCT05870969)
- Testing
- Liver cancer surveillance every 3 months, Liver cancer surveillance every 6 months, Liver cancer surveillance annually
- Where
- China
- Volunteers
- 20,000 people
- Sponsor
- Ruijin Hospital
Hepatitis D, Hepatitis C
Evaluation of Patients With Liver Disease
The proposed study aims to evaluate, investigate, and follow-up patients suffering from acute and chronic liver disease. The study will focus on understanding diseases affecting the liver.
- Conditions
- Hepatitis D, Hepatitis C, Hepatitis B, Liver Disease
- Trial name
- NCT00001971
- Where
- United States
- Volunteers
- 8,050 people, healthy volunteers welcome
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Chronic Hepatitis B, HEPATITIS C VIRUS CHRONIC INFECTION
Hepatitis Inequalities Study
Health inequality in liver diseases including age, gender, ethnicity and socioeconomic status has been increasingly recognised and potentially hinder hepatitis elimination.
- Trial name
- NCT06596213
- Volunteers
- 100,000 people
- Sponsor
- Chinese University of Hong Kong
Cancer, Liver Cirrhosis
Collection of Blood From Healthy Patients, Patients With Benign Disease and Patients With Cancer
To acquire blood samples from subjects for various purposes, including: i) determining the sensitivity and specificity of select DNA methylation markers for the detection of various types of cancer, ii) identifying benign…
- Conditions
- Cancer, Liver Cirrhosis, Chronic Hepatitis, Hepatitis B
- Trial name
- ELITE (NCT05181826)
- Testing
- Multi-analyte Blood Test
- Where
- 7 sites in United States
- Volunteers
- 1,200 people
- Sponsor
- Helio Genomics
Hepatitis C
Strategic Treatment Reduction in Very Early Liver Disease With 4 Weeks Sofosbuvir Plus Glecepravir-pibrentasvir
This study aims to evaluate the efficacy, safety and feasibility of four weeks of sofosbuvir plus glecaprevir-pibrentasvir, followed by immediate retreatment of virological relapse with glecepravir-pibrentasvir for 12 weeks, in…
- Trial name
- STRIVE-4 (NCT03855917)
- Testing
- Sofosbuvir 400mg [Sovaldi], Glecaprevir/pibrentasvir (300mg/120mg)
- Where
- 3 sites in Australia
- Volunteers
- 30 people
- Sponsor
- Kirby Institute
Chronic Hepatitis C, Medication Reaction
The Efficacy of Vosevi in Treating DAA-experienced Patients
Hepatitis C virus (HCV) infection remains a significant health problem in our country. The World Health Organization estimated that 71 million people worldwide had chronic HCV infection in 2015.
- Trial name
- NCT06180590
- Testing
- Sofosbuvir / Velpatasvir / Voxilaprevir Oral Tablet [Vosevi]
- Where
- China
- Volunteers
- 200 people
- Sponsor
- The Third Affiliated Hospital of Guangzhou Medical University
Diabetes Mellitus, Hepatitis C, Chronic
People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents
Background: Chronic hepatitis C infects the liver. It may scar the liver. This is called cirrhosis and may lead to liver cancer or death. Current chronic hepatitis C treatments cure most people.
- Conditions
- Diabetes Mellitus, Hepatitis C, Chronic, Cardiovascular Diseases
- Trial name
- NCT03520660
- Testing
- Epclusa
- Where
- United States
- Volunteers
- 121 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Liver Transplant, Hepatitis C
Proteogenomic Monitoring and Assessment of Liver Transplant Recipients
This study is being done to test blood, urine and tissue samples to see if this can help decide if CKD (Chronic Kidney Disease), AR (Acute Rejection) and HCV (Hepatitis C Virus) can be identified in its early stages.
- Conditions
- Liver Transplant, Hepatitis C, Chronic Kidney Disease, Acute Rejection
- Trial name
- "Mini-Liver" (NCT01644903)
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Northwestern University
Cirrhosis, Cirrhosis, Liver
Liver Cirrhosis Network Cohort Study
Liver Cirrhosis Network (LCN) Cohort Study is an observational study designed to identify risk factors and develop prediction models for risk of decompensation in adults with liver cirrhosis.
- Conditions
- Cirrhosis, Cirrhosis, Liver, Cirrhosis Early, Cirrhosis Due to Hepatitis B
- Trial name
- LCN-C (NCT05740358)
- Where
- 14 sites in United States
- Volunteers
- 1,222 people
- Sponsor
- Northwestern University
Chronic Hepatitis C Infection
HEPATITIS C SCREENING in ADULTS with RISK FACTORS in FIVE CITIES of COLOMBIA'S CARIBBEAN COAST (FIVE-CC)
Hepatitis C virus (HCV) infection is a significant cause of chronic hepatitis, cirrhosis, and liver cancer (1). The risk of developing cirrhosis in people with chronic HCV infection ranges between 15% and 30% over a period of 20…
- Trial name
- FIVE-CC (NCT06899542)
- Volunteers
- 4,000 people, healthy volunteers welcome
- Sponsor
- Diana Rocio Chavez Bejarano